Trial Profile
Phase II Trial of ONTAK [denileukin diftitox] with Metastatic Melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2014
Price :
$35
*
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 22 Sep 2011 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 06 Aug 2010 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Sep 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.